ACM
ESPR

AlphaCrest Capital Management’s Esperion Therapeutics ESPR Stock Holding History

AlphaCrest Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,100
Closed -$702K – 1268
2019
Q2 		$702K Buy
+15,100
New +$709K 0.06% 559

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AlphaCrest Capital Management's ESPR Position: Q3 2019 in Review

AlphaCrest Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 15,100 shares — an estimated $702K sold.

AlphaCrest Capital Management first reported a position in ESPR in Q2 2019 and held it in 1 quarter. The position peaked at $702K in Q2 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • AlphaCrest Capital Management reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • AlphaCrest Capital Management sold 15,100 Esperion Therapeutics shares in Q3 2019, an estimated $702K.
  • AlphaCrest Capital Management first reported a position in Esperion Therapeutics in Q2 2019 and held it in 1 quarter.
  • AlphaCrest Capital Management's Esperion Therapeutics position peaked at $702K in Q2 2019.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on AlphaCrest Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.